DOCSLIB.ORG

Neurotechnologies and Brain Computer Interface

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

From Technologies to Market Sample Neurotechnologies and brain computer interface Market and Technology analysis 2018 LIST OF COMPANIES MENTIONED IN THIS REPORT 240+ slides of market and technology analysis Abbott, Ad-tech, Advanced Brain Monitoring, AdvaStim, AIST, Aleva Neurotherapeutics, Alphabet, Amazon, Ant Group, ArchiMed, Artinis Medical Systems, Atlas Neuroengineering, ATR, Beijing Pins Medical, BioSemi, Biotronik, Blackrock Microsystems, Boston Scientific, Brain products, BrainCo, Brainscope, Brainsway, Cadwell, Cambridge Neurotech, Caputron, CAS Medical Systems, CEA, Circuit Therapeutics, Cirtec Medical, Compumedics, Cortec, CVTE, Cyberonics, Deep Brain Innovations, Deymed, Dixi Medical, DSM, EaglePicher Technologies, Electrochem Solutions, electroCore, Elmotiv, Endonovo Therapeutics, EnerSys, Enteromedics, Evergreen Medical Technologies, Facebook, Flow, Foc.us, G.Tec, Galvani Bioelectronics, General Electric, Geodesic, Glaxo Smith Klein, Halo Neurosciences, Hamamatsu, Helius Medical, Technologies, Hitachi, iBand+, IBM Watson, IMEC, Integer, Integra, InteraXon, ISS, Jawbone, Kernel, LivaNova, Mag and More, Magstim, Magventure, Mainstay Medical, Med-el Elektromedizinische Geraete, Medtronic, Micro Power Electronics, Micro Systems Technologies, Micromed, Microsoft, MindMaze, Mitsar, MyBrain Technologies, Natus, NEC, Nemos, Nervana, Neurable, Neuralink, NeuroCare, NeuroElectrics, NeuroLutions, NeuroMetrix, Neuronetics, Neuronetics, Neuronexus, Neuropace, Neuros Medical, Neuroscan, NeuroSigma, NeuroSky, Neurosoft, Neurostar, Neurowave, Nevro, Nexeon, Nexstim, Nielsen, Nihon Kohden, Nirox, Nonin Medical, Nuvectra, Olympus, Ornim, Oscor, Pacesetter, Panasonic, Paradromics, Philips, Plexon, PMT Corporation, RetroSense, Rhythm, Ripple, Rythm Dreem, Samsung, SceneRay, Second Sight Medical, Sensomedical, Setpoint Medical, Shimadzu, Siemens, Sony, Sorin Group, Soterix Medical, SPR Therapeutics, Stim Wave, Teijin, Thync, Toyota, Verily, VieLight, Vygon, Ximedica, Ybrain, And many more !! Information gathered through direct discussions with technology developers, end-users and key opinion leaders ©2018 | www.yole.fr | Neurotechnologies and brain computer interface 2 ABOUT THE AUTHORS Biographies & contacts Jérôme Mouly Jerôme Mouly serves as a Technology & Market Analyst specialized in microtechnologies for biomedical & medical imaging applications at Yole Développement (Yole). Since 2000, Jérôme has participated in more than 100 marketing and technological analyses for industrial groups, start-ups and institutes related to semiconductor & medical technologies industry. Jérôme holds a Master of Physics from the University of Lyon. Dr. Marjorie Villien As a Technology & Market Analyst, Dr. Marjorie Villien is member of the Medical Technologies business unit at Yole Développement (Yole). She is a daily contributor to the development of these activities with a dedicated collection of market & technology reports as well as custom consulting projects. After spending two years at Harvard and prior Yole, Marjorie served as a research scientist at INSERM. Marjorie Villien is graduated from Grenoble INP and holds a PhD in physics & medical imaging. KnowMade’s team realized the patent analysis: Dr Coralie Le Greneur Dr Coralie Le Greneur works for Knowmade in the field of Biotechnology and Life Sciences. She holds a PhD in Molecular Biology from the University of Nice Sophia- Antipolis (France). She also holds the International Industrial Studies Diploma in Patents from the CEIPI, Strasbourg (France). Dr. Brice Sagot Dr. Brice Sagot is COO and cofounder of Knowmade. He is leading the Biotechnology and Life Sciences department. He holds a PhD in molecular biology from the University of Nice Sophia-Antipolis, France. 3 OBJECTIVES OF THIS REPORT • Explain the challenges linked to neurotechnologies, and their current/ future applications • Offer a technical and economic segmentation of the neurotechnologies field: neurosensing, neurostimulation, and brain computer interface (BCI) • Deliver an overview of neurotechnologies’ main players and their respective technologies • Furnish market data and forecasts for the period 2017 - 2035, and market dynamics for each segment • Provide neurotechnology roadmaps and an overview of the latest innovations in each segment • Understand the most active companies through a comprehensive patents list for neurostimulation and neurosensing 4 WHO SHOULD BE INTERESTED BY THIS REPORT? o Pharmaceutical and medical device companies: o Medical devices outsourcing companies: • To understand what is state of the art in • To have a broad overview of all neurotechnology neurotechnology applications & markets • To identify the different players across the supply • chain To identify new markets • To get a list of selected players in the field of • To monitor and benchmark potential neurotechnology both in the market and in competitors development • To understand behavior evolution • To understand behavior evolution and identify • To identify the key challenges linked to hardware new business models in the field of neurotechnology • To identify competitors and targets for collaborations or M&A o Financial & Strategic investors: o Equipment & Material suppliers: • To understand the potential for neurotechnology • To understand the technical evolution of devices in the consumer and healthcare neurotechnology devices. industries • To identify business opportunities and prospects • To know the latest trends within the industry • To get a list of players in the field of o R&D players: neurotechnology and their activities • To understand new challenges in neurotechnology 5 TABLE OF CONTENTS • Executive Summary 10 • Patent landscape by KnowMade • Company profiles • Introduction 55 • How does the brain work? • Neurostimulation 153 • Neurological disorders • Main players and market share • Brain Initiative • Market data and forecasts 2017 – 2023 by technology (DBS, SCS, VNS, TMS, • Scope of the report TDCS, etc.) and by application (clinical, research, consumer) • Main technologies and roadmaps • Segmentation of the Neurotechnology Market 67 • Patent landscape by KnowMade • Technological and behavioral/economical criteria • Company profiles • Segmentation • Brain Computer Interface 204 • Market Analysis 71 • Main players • Mergers and acquisitions • Market data and forecasts 2017 – 2023 by applications • Fundraising analysis • Main technologies and roadmaps • Market data and forecasts 2017-2023 • Company profiles • Neurotechnology ecosystems • IOMT in the neurotechnology business • Supply Chain Analysis 227 • Roadmaps • General Conclusions 233 • Forecasts 2017-2035 using the model of the DNA sequencing history • Annex - Patent Landscape Methodology 238 • Neurosensing 90 • Main players and market share • Market data and forecasts 2017 – 2023: system level and electrodes level, by technology and by application • EEG value chain • Main technologies and roadmaps 6 INTRODUCTION TO NEUROTECHNOLOGY How does the brain work? (1/2) • The brain is made of a lot of different types of cells: • Neurons : electrically excitable cells that receive, process, and transmit information through electrical and chemical signals • Microglia : immune system • Oligodendrocytes : provide support and insulation to axons • Astrocytes : variety of tasks, from axon guidance and synaptic support, to the Most of the control of the blood brain barrier and blood flow technologies aiming at interacting with • The axon of the neuron is responsible for conveying an action potential from the brain target the cell body to the axon terminus. An action potential is an electrical signal the electrical resulting from a sudden, transient change in membrane potential. signaling pathway of the neurons 7 INTRODUCTION TO NEUROTECHNOLOGY How does the brain work? (2/2) • When an action potential reaches an axon terminal it triggers the release of neurotransmitters into the synaptic cleft which diffuses and binds receptors on the postsynaptic neuron. • Sufficient binding will cause the postsynaptic neuron to “fire”. • There are two kinds of neurotransmitters : • Excitatory neurotransmitters stimulate the brain. Electrical events propagate the • Inhibitory neurotransmitters calm the brain and help create balance. signal within a neuron and chemical processes transmit the signal from one neuron to another 8 INTRODUCTION TO NEUROTECHNOLOGY Neurological disorders Worldwide prevalence of most neurological disorders (in millions people affected) 100 350M 1,140M 90 80 70 Up to 1 billion 60 people, nearly 50 one in six of 40 30 the world's 20 population, 10 suffer from Millions peopleaffected - neurological disorders Non- Source: WHO Psychiatric Trauma Infections Degeneration Tumors Vascular psychiatric disorders disorders 9 INTRODUCTION TO NEUROTECHNOLOGY Scope of the report Included in this report are neurotechnologies Not included in the scope of this report are which directly interact with/touch the patient, neurotechnologies based on medical imaging such as neurosensing technologies (EEG, ECoG, systems not directly interacting with the patient NIRS, etc.), neurostimulation (DBS, VNS, TDCS, (MRI, MEG, PET, etc.), cochlear implants and etc.) and brain computer interfaces. retinal prosthesis. Scope: Neurotechnologies directly interacting with patients 10 SEGMENTATION OF THE NEUROTECHNOLOGY MARKET Technological Invasive Non invasive Invasive Non invasive Invasiveness Behavioral criteria criteria Electrical Light Magnetic Ultrasound Technology Electro-corticography, Electro- Near infrared
Recommended publications
  • Neural Dust: Ultrasonic Biological Interface

    Neural Dust: Ultrasonic Biological Interface

    Neural Dust: Ultrasonic Biological Interface Dongjin (DJ) Seo Electrical Engineering and Computer Sciences University of California at Berkeley Technical Report No. UCB/EECS-2018-146 http://www2.eecs.berkeley.edu/Pubs/TechRpts/2018/EECS-2018-146.html December 1, 2018 Copyright © 2018, by the author(s). All rights reserved. Permission to make digital or hard copies of all or part of this work for personal or classroom use is granted without fee provided that copies are not made or distributed for profit or commercial advantage and that copies bear this notice and the full citation on the first page. To copy otherwise, to republish, to post on servers or to redistribute to lists, requires prior specific permission. Neural Dust: Ultrasonic Biological Interface by Dongjin Seo A dissertation submitted in partial satisfaction of the requirements for the degree of Doctor of Philosophy in Engineering - Electrical Engineering and Computer Sciences in the Graduate Division of the University of California, Berkeley Committee in charge: Professor Michel M. Maharbiz, Chair Professor Elad Alon Professor John Ngai Fall 2016 Neural Dust: Ultrasonic Biological Interface Copyright 2016 by Dongjin Seo 1 Abstract Neural Dust: Ultrasonic Biological Interface by Dongjin Seo Doctor of Philosophy in Engineering - Electrical Engineering and Computer Sciences University of California, Berkeley Professor Michel M. Maharbiz, Chair A seamless, high density, chronic interface to the nervous system is essential to enable clinically relevant applications such as electroceuticals or brain-machine interfaces (BMI). Currently, a major hurdle in neurotechnology is the lack of an implantable neural interface system that remains viable for a patient's lifetime due to the development of biological response near the implant.
  • Towards a UK Neurotechnology Strategy

    Towards a UK Neurotechnology Strategy

    Towards a UK Neurotechnology Strategy A UK ecosystem for Neurotechnology: Development, commercial exploitation and societal adoption Prof. Keith Mathieson (Chair) | Prof. Tim Denison (Co-chair) | Dr. Charlie Winkworth-Smith 1 Towards a UK Neurotechnology Strategy Towards a UK Neurotechnology Strategy Contents Executive Summary 05 A UK Eco-System for Neurotechnology: Development, Commercial Exploitation and Societal Adoption 06 The UK 08 Our Proposed Approach 12 Case Study: Retinal Prosthetics 15 Uses of Neurotechnology 18 Bioelectronic Medicine 18 Brain-Computer Interfaces 19 Human Cognitive Augmentation 21 Development of New Neurotechnologies Provides Non-Pharmaceutical Alternatives to Chronic Pain Relief 22 Overview of the UK Neurotechnology Landscape 24 Opportunities for the UK 29 Steering Group 30 We will create a shared vision for the UK to be a world leader in neurotechnology. 2 1 https://www.internationalbraininitiative.org/ 3 Executive Summary Recent funding initiatives have changed the global neurotechnology landscape, with the US, China, Japan, the EU, Canada and Australia all investing at scale in 10 year+ programmes. In particular, the US has seen an investment of $1.7 billion since 2014 in their national programme1. The resultant rapid maturation of the academic research has led to sophisticated clinical devices capable of treating neurodegenerative conditions in patients and to a burgeoning commercial sector. The UK, with its outstanding neuroscience, medical and engineering expertise, has an exciting opportunity to make a valuable contribution to the leadership of this international effort. Vision: In response to this opportunity our vision is to bring together the existing strengths and form a cohesive UK eco-system to accelerate commercial and economic opportunities from neurotechnology science and engineering research.

  • Selected Topics in Neuroplastic & Reconstructive Surgery

    CONTINUING MEDICAL EDUCATION Fifth Annual Selected Topics in Neuroplastic & Reconstructive Surgery: An International Symposium on Cranioplasty and Implantable Neurotechnology with Cadaver Lab Presented by: Department of Plastic-Reconstructive Surgery & Department of Neurosurgery Section of Neuroplastic & Reconstructive Surgery Johns Hopkins University School of Medicine Jointly Provided by: Society of Neuroplastic Surgery November 2-3, 2019 General Session – November 2 Hands-on Lab – November 3 The Rotunda Boston Bioskills Lab Joseph B. Martin Conference Center Boston, Massachusetts at Harvard Medical School Boston, Massachusetts This activity endorsed by: American Society of Maxillofacial Surgeons NEW American Society of Plastic Surgeons THIS YEAR! Oral Abstract Congress of Neurological Surgeons Session Global Neuro Society of Neuroplastic Surgery This activity has been approved for AMA PRA Category 1 Credits™. DESCRIPTION Modern-day cranioplasty, along with the burgeoning field of Neuroplastic and Reconstructive Surgery, is undergoing a significant paradigm shift related to various techniques, surgical advancements, implantable neurotechnology, and improved biomaterials. These changes have stimulated us to assemble premier thought leaders in various specialties including neurosurgery, neuroplastic surgery, craniofacial surgery, and plastic surgery to meet for the FIFTH annual symposium dedicated to the subjects of “cranioplasty”, “implantable neurotechnology”, and “neuroplastic surgery”—to be hosted this year at the Joseph B. Martin Conference Center at Harvard Medical School in Boston, Massachusetts. The faculty will gather to present evidence-based data on surgical approaches and state-of-the-art materials, engage and network within a broad array of colleagues and experts, and share high-yield experiences to help attendees improve their patient outcomes. Interactive panel discussions following each lecture will offer the opportunity to debate the evidence, exchange ideas, and gain invaluable insight to assist with the most challenging cases.
  • Implantable Microelectrodes on Soft Substrate with Nanostructured Active Surface for Stimulation and Recording of Brain Activities Valentina Castagnola

    Implantable Microelectrodes on Soft Substrate with Nanostructured Active Surface for Stimulation and Recording of Brain Activities Valentina Castagnola

    Implantable microelectrodes on soft substrate with nanostructured active surface for stimulation and recording of brain activities Valentina Castagnola To cite this version: Valentina Castagnola. Implantable microelectrodes on soft substrate with nanostructured active sur- face for stimulation and recording of brain activities. Micro and nanotechnologies/Microelectronics. Universite Toulouse III Paul Sabatier, 2014. English. tel-01137352 HAL Id: tel-01137352 https://hal.archives-ouvertes.fr/tel-01137352 Submitted on 31 Mar 2015 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. THÈSETHÈSE En vue de l’obtention du DOCTORAT DE L’UNIVERSITÉ DE TOULOUSE Délivré par : l’Université Toulouse 3 Paul Sabatier (UT3 Paul Sabatier) Présentée et soutenue le 18/12/2014 par : Valentina CASTAGNOLA Implantable Microelectrodes on Soft Substrate with Nanostructured Active Surface for Stimulation and Recording of Brain Activities JURY M. Frédéric MORANCHO Professeur d’Université Président de jury M. Blaise YVERT Directeur de recherche Rapporteur Mme Yael HANEIN Professeur d’Université Rapporteur M. Pascal MAILLEY Directeur de recherche Examinateur M. Christian BERGAUD Directeur de recherche Directeur de thèse Mme Emeline DESCAMPS Chargée de Recherche Directeur de thèse École doctorale et spécialité : GEET : Micro et Nanosystèmes Unité de Recherche : Laboratoire d’Analyse et d’Architecture des Systèmes (UPR 8001) Directeur(s) de Thèse : M.
  • Non-Invasive Neurostimulation Methods for Acute and Preventive Migraine Treatment—A Narrative Review

    Non-Invasive Neurostimulation Methods for Acute and Preventive Migraine Treatment—A Narrative Review

    Journal of Clinical Medicine Review Non-Invasive Neurostimulation Methods for Acute and Preventive Migraine Treatment—A Narrative Review Stefan Evers 1,2 1 Faculty of Medicine, University of Münster, 48153 Münster, Germany; [email protected] 2 Department of Neurology, Lindenbrunn Hospital, 31863 Coppenbrügge, Germany Abstract: Neurostimulation methods have now been studied for more than 20 years in migraine treatment. They can be divided into invasive and non-invasive methods. In this narrative review, the non-invasive methods are presented. The most commonly studied and used methods are vagal nerve stimulation, electric peripheral nerve stimulation, transcranial magnetic stimulation, and transcranial direct current stimulation. Other stimulation techniques, including mechanical stimulation, play only a minor role. Nearly all methods have been studied for acute attack treatment and for the prophylactic treatment of migraine. The evidence of efficacy is poor for most procedures, since no stimulation device is based on consistently positive, blinded, controlled trials with a sufficient number of patients. In addition, most studies on these devices enrolled patients who did not respond sufficiently to oral drug treatment, and so the role of neurostimulation in an average population of migraine patients is unknown. In the future, it is very important to conduct large, properly blinded and controlled trials performed by independent researchers. Otherwise, neurostimulation methods will only play a very minor role in the treatment of migraine. Keywords: neurostimulation; vagal nerve; supraorbital nerve; transcranial magnetic stimulation Citation: Evers, S. Non-Invasive Neurostimulation Methods for Acute and Preventive Migraine 1. Introduction Treatment—A Narrative Review. J. One of the recent innovations in migraine treatment was the detection of several types Clin.
  • Use of Neurotechnology in Normal Brain Aging and Alzheimer

    Use of Neurotechnology in Normal Brain Aging and Alzheimer

    Use of Neurotechnology in Normal Brain Aging and Alzheimer’s Disease (AD) and AD-Related Dementias (ADRD) NIA Virtual Workshop Division of Neuroscience April 27, 2020 Final June 1, 2020 This meeting summary was prepared by Dave Frankowski, Rose Li and Associates, Inc., under contract to the National Institute on Aging (NIA). The views expressed in this document reflect both individual and collective opinions of the focus group participants an d not necessarily those of NIA. Review of earlier versions of this meeting summary by the following individuals is gratefully acknowledged: Ali Abedi, Ed Boyden, Dana Carluccio, Monica Fabiani, Mariana Figueiro, Jay Gupta, Ben Hampstead, Marie Hayes, Abhishek Rege, Fiza Singh, Nancy Tuvesson, Shuai Xu. Neurotechnology in Normal Brain Aging, AD, and ADRD April 27, 2020 Table of Contents Executive Summary ............................................................................................................... 1 Meeting Summary ................................................................................................................. 3 Welcome and Opening Remarks .............................................................................................................. 3 Using Non-invasive Sensory Stimulation to Ameliorate Alzheimer’s Disease Pathology and Symptoms 3 Flipping the Switch: How to Use Light to Improve the Lives and Health of Persons with Alzheimer’s Disease and Related Dementias ..............................................................................................................
  • History, Applications, and Mechanisms of Deep Brain Stimulation

    History, Applications, and Mechanisms of Deep Brain Stimulation

    NEUROLOGICAL REVIEW SECTION EDITOR: DAVID E. PLEASURE, MD History, Applications, and Mechanisms of Deep Brain Stimulation Svjetlana Miocinovic, MD, PhD; Suvarchala Somayajula, MD; Shilpa Chitnis, MD, PhD; Jerrold L. Vitek, MD, PhD eep brain stimulation (DBS) is an effective surgical treatment for medication-refractory hypokinetic and hyperkinetic movement disorders, and it is being explored for a variety of other neurological and psychiatric diseases. Deep brain stimulation has been Food and Drug Administration–approved for essential tremor and Parkinson disease and has Da humanitarian device exemption for dystonia and obsessive-compulsive disorder. Neurostimulation is the fruit of decades of both technical and scientific advances in the field of basic neuroscience and functional neurosurgery. Despite the clinical success of DBS, the therapeutic mechanism of DBS re- mains under debate. Our objective is to provide a comprehensive review of DBS focusing on move- ment disorders, including the historical evolution of the technique, applications and outcomes with an overview of the most pertinent literature, current views on mechanisms of stimulation, and de- scription of hardware and programming techniques. We conclude with a discussion of future devel- opments in neurostimulation. JAMA Neurol. 2013;70(2):163-171. Published online November 12, 2012. doi:10.1001/2013.jamaneurol.45 Deep brain stimulation (DBS) has evolved recovery.1-4 New applications continue to as an important therapy for the treat- emerge, encouraged by past successes and ment of essential tremor, Parkinson dis- the fact that DBS effects are reversible al- ease (PD), and dystonia, and it is also lowing exploration of new targets and ap- emerging for the treatment of medication- plications not previously possible with le- refractory psychiatric disease.
  • State-Of-The-Art BCI Device Technology

    State-Of-The-Art BCI Device Technology

    State-of-the-Art BCI Device Technology Jose L. Contreras-Vidal, Ph.D. University of Houston STATE OF THE ART PATIENT BCI SOLUTIONS (CORTICAL INVASIVE AND NONINVASIVE, PERIPHERAL) Jose L Contreras-Vidal, PhD Hugh Roy and Lillie Cranz Cullen University Professor Department of Electrical & Computer Engineering University of Houston http://www.ee.uh.edu/faculty/contreras-vidal https://www.facebook.com/UHBMIST Scope • “Neuroprostheses that interface with the central or peripheral nervous system to restore lost motor or sensory capabilities” (FDA’s working definition of BCI) • BCI Devices for Patients with Paralysis and Amputation • Cortical (invasive and noninvasive) and Peripheral • Human investigational studies of BCI devices reported in clinicaltrials.gov Working definition of BCI systems Neural interface – Recording electrode 1 3 Prosthetic, exoskeleton, robotic or virtual effector (usually + shared control) 2 Feedback system – Definitions: Neural stimulator 1 – interface, physical/virtual effector Closed loop 2 – interface, physical effector feedback 3 – interface, feedback Sensor – response system Neural Interface to prosthetic, exoskeleton, robotic or virtual effector (definition 1) Research Clinical Studies Cleared/Approved Myoelectric prosthetic High DOF prosthetic, myoelectric + shared control Invasive cortical interface EEG interface BCI systems Implantable myoelectric sensor Exoskeleton Novel cortical interface * Dry contact EEG * * Not reviewed here. Peripheral nerve sensors * Neural Interface to prosthetic, exoskeleton, robotic
  • 9.123 Lecture 1 Introduction to Neurotechnology Notes

    9.123 Lecture 1 Introduction to Neurotechnology Notes

    NEUROTECHNOLOGY IN ACTION 9.123/20.203 Courtesy of digitalbob8 on Flickr. License CC BY. 1 life before neurotechnology… Image is in public domain. Image is in public domain. The Iconographic Encyclopaedia of Science, Literature and Art, 1851, via Wikimedia Commons. 2 modern optics and staining: delineation of the neuron! Zeiss ! microscope 1870 Golgi stain (1873)! Ramon y Cajal neural microanatomy (1894)! Image is in public domain. Image is in public domain. 3 electrophysiology: electrical behavior of neurons Hodgkin-Huxley model (1952) Image is in public domain. © Nobel Media AB. All rights reserved. This content is excluded from our Creative Commons license. For more information, see http://ocw.mit.edu/help/faq-fair-use/. 4 brain imaging: noninvasive studies of structure and function X-ray CT (1971) MRI (1973)! Courtesy of the Laboratory of Neuro Imaging and Martinos Center for Biomedical Imaging, Consortium of the Human Connectome Project - www.humanconnectomeproject.org. PET (1975) Image is in public domain. Image is in public domain. 5 continuing innovation rapid growth (diversity wanted) © All rights reserved. This content is excluded from our Creative Commons license. For more information, see http://ocw.mit.edu/help/faq-fair-use/. 6 National Academy of Engineering. Accessed October 14, 2010. http://www.nationalacademies.org. The WHITEHOUSE. "Brain Initiative." Accessed April 2, 2013. https://www.whitehouse.gov/BRAIN. Human Brain Project. https://www.humanbrainproject.eu/. 7 the scale of the brain… numerous brain regions macroscale to nanoscale 1011 neurons 1014 synapses Courtesy of Allan Ajifo on Flickr. CC license BY. 8 “forest” of cell types the complexity of the brain… complex interconnectivity cellular and subcellular features Image of neural signaling is in public domain.
  • Introduction. Advances and Future Directions in Brain Mapping In

    Introduction. Advances and Future Directions in Brain Mapping In

    NEUROSURGICAL FOCUS Neurosurg Focus 48 (2):E1, 2020 INTRODUCTION Advances and future directions in brain mapping in neurosurgery Alexandra J. Golby, MD,1 Eric C. Leuthardt, MD, FNAI,2 Hugues Duffau, MD, PhD,3 and Mitchel S. Berger, MD4 1Department of Neurosurgery, Department of Radiology, Harvard Medical School, Brigham and Women’s Hospital, Boston, Massachusetts; 2Department of Neurological Surgery, Division of Neurotechnology, Washington University, St. Louis, Missouri; 3Department of Neurosurgery, Gui de Chauliac Hospital, Montpellier University Medical Center, National Institute for Health and Medical Research (INSERM), U1051 Laboratory, Institute for Neurosciences of Montpellier, France; and 4Department of Neurological Surgery, Brain Tumor Research Center, University of California, San Francisco, California EUROSURGEONS have been directly involved with guide glioma surgery, whereas Fernández et al. provide an brain mapping efforts for well over a century. Di- in-depth investigation of the white matter associated with rect access to the functioning human brain during Heschl’s gyrus. Three papers focus on a variety of aspects surgeryN for intrinsic brain tumors, epilepsy, and functional related to functional MRI (fMRI): Catalino et al. review neurosurgical procedures both requires individual func- the use of resting fMRI for surgical planning, Nolan et tional brain mapping and presents an opportunity to pre- al. studied a patient with a heterotopia, and Stopa et al. cisely map human brain function. Several papers in this surveyed clinicians regarding their use of fMRI. Finally, issue of Neurosurgical Focus extend our current under- two papers, one by Azad and Duffau and the other by Ellis standing of cerebral organization with detailed examina- et al., discuss mapping using noninvasive methods such tion of specific regions.
  • Wireless, Battery-Free, and Fully Implantable Electrical

    Wireless, Battery-Free, and Fully Implantable Electrical

    Burton et al. Microsystems & Nanoengineering (2021) 7:62 Microsystems & Nanoengineering https://doi.org/10.1038/s41378-021-00294-7 www.nature.com/micronano ARTICLE Open Access Wireless, battery-free, and fully implantable electrical neurostimulation in freely moving rodents Alex Burton1,SangMinWon 2, Arian Kolahi Sohrabi3, Tucker Stuart1, Amir Amirhossein1,JongUkKim4, ✉ ✉ ✉ Yoonseok Park 4, Andrew Gabros3,JohnA.Rogers 4,5,6,7,8,9 , Flavia Vitale10 ,AndrewG.Richardson 3 and ✉ Philipp Gutruf 1,11,12 Abstract Implantable deep brain stimulation (DBS) systems are utilized for clinical treatment of diseases such as Parkinson’s disease and chronic pain. However, long-term efficacy of DBS is limited, and chronic neuroplastic changes and associated therapeutic mechanisms are not well understood. Fundamental and mechanistic investigation, typically accomplished in small animal models, is difficult because of the need for chronic stimulators that currently require either frequent handling of test subjects to charge battery-powered systems or specialized setups to manage tethers that restrict experimental paradigms and compromise insight. To overcome these challenges, we demonstrate a fully implantable, wireless, battery-free platform that allows for chronic DBS in rodents with the capability to control stimulation parameters digitally in real time. The devices are able to provide stimulation over a wide range of frequencies with biphasic pulses and constant voltage control via low-impedance, surface-engineered platinum electrodes. The devices utilize off-the-shelf components and feature the ability to customize electrodes to enable 1234567890():,; 1234567890():,; 1234567890():,; 1234567890():,; broad utility and rapid dissemination. Efficacy of the system is demonstrated with a readout of stimulation-evoked neural activity in vivo and chronic stimulation of the medial forebrain bundle in freely moving rats to evoke characteristic head motion for over 36 days.
  • Combined Occipital and Supraorbital Neurostimulation for the Treatment of Chronic Migraine Headaches: Initial Experienceceph 1996 1..13

    Combined Occipital and Supraorbital Neurostimulation for the Treatment of Chronic Migraine Headaches: Initial Experienceceph 1996 1..13

    doi:10.1111/j.1468-2982.2009.01996.x Combined occipital and supraorbital neurostimulation for the treatment of chronic migraine headaches: initial experienceceph_1996 1..13 KL Reed1, SB Black2, CJ Banta II3 &KRWill1 1Department of Anesthesiology, Presbyterian Hospital of Dallas, 2Medical Director of Neurology, Baylor University Medical Center of Dallas, and 3Department of Orthopedic Surgery, Presbyterian Hospital of Dallas, Dallas, TX, USA Reed KL, Black SB, Banta CJ II & Will KR. Combined occipital and supraorbital neurostimulation for the treatment of chronic migraine headaches: initial expe- rience. Cephalalgia 2009. London. ISSN 0333-1024 A novel approach to the treatment of chronic migraine headaches based on neurostimulation of both occipital and supraorbital nerves was developed and reduced to clinical practice in a series of patients with headaches unresponsive to currently available therapies. Following positive trials, seven patients with chronic migraine and refractory chronic migraine headaches had permanent combined occipital nerve–supraorbital nerve neurostimulation systems implanted. The relative responses to two stimulation programs were evaluated: one that stimulated only the occipital leads and one that stimulated both the occipital and supraorbital leads together. With follow-up ranging from 1 to 35 months all patients reported a full therapeutic response but only to combined supraorbital–occipital neurostimulation. Occipital nerve stimulation alone pro- vided a markedly inferior and inadequate response. Combined occipital nerve– supraorbital nerve neurostimulation systems may provide effective treatment for patients with chronic migraine and refractory chronic migraine headaches. For patients with chronic migraine headaches the response to combined systems appears to be substantially better than occipital nerve stimulation alone. ᮀMigraine, chronic migraine, refractory migraine, peripheral nerve stimulation, occipi- tal nerve stimulation, supraorbital nerve stimulation Kenneth L.